2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-106616
    Muzolimine 55294-15-0 98.22%
    Muzolimine (BAY-g 282) is a slow and long lasting diuresis agent. Muzolimine produces a diuresis in the loop of Henle and also shows anti-hypertensive and natriuresis effects. Muzolimine can be used for the research of cardiovascular disease.
    Muzolimine
  • HY-106690
    Centhaquin 57961-90-7 99.93%
    Centhaquine (Centhaquin; PMZ-2010) is a novel agent has the potential for treatment of haemorrhagic shock. Centhaquine (Centhaquin; PMZ-2010) can augment cardiac output, reduce systemic vascular resistance in haemorrhagic models.
    Centhaquin
  • HY-107203
    Propentofylline 55242-55-2 99.88%
    Propentofylline (HWA 285) is an orally active and brain-penetrant phosphodiesterase inhibitor. Propentofylline blocks adenosine reuptake and prevents cyclic nucleotide degradation. Propentofylline can be used for the research of primary degenerative (Alzheimer's) dementia, vascular dementia, cerebral ischemia, acute stroke, and learning and memory disorders.
    Propentofylline
  • HY-107337
    Delapril hydrochloride 83435-67-0 98.0%
    Delapril hydrochloride is an angiotensin-converting enzyme (ACE) inhibitor for the treatment of cardiovascular diseases.
    Delapril hydrochloride
  • HY-107579
    Acifran 72420-38-3 ≥99.0%
    Acifran (AY 25712), an antihyperlipidemic agent, is an orally active agonist of GPR109A (HM74A) and GPR109B, the high and low affinity receptors for Niacin.
    Acifran
  • HY-108765
    Ferric carboxymaltose 53858-86-9
    Ferric carboxymaltose is an iron supplement.
    Ferric carboxymaltose
  • HY-109122
    Selatogrel 1159500-34-1 99.75%
    Selatogrel (ACT-246475) is a reversible and selective P2Y12 receptor antagonist which inhibits platelet aggregation with an IC50 of 8 nM. Selatogrel exhibits antithrombotic efficacy.
    Selatogrel
  • HY-109592
    Imidaprilate 89371-44-8 99.0%
    Imidaprilate is an active metabolite of TA-6366, acts as a potent angiotensin converting enzyme (ACE) inhibitor, with an IC50 of 2.6 nM, and is used in the research of hypertensive disease.
    Imidaprilate
  • HY-110140
    (E)-KN-93 phosphate 1188890-41-6 99.85%
    (E)-KN-93 phosphate is a Ca2+/calmodulin-dependent protein kinase II (CaMKII) inhibitor with IC50 values of 9 μM and 3 μM against CaMKIIδMonomer and CaMKIIδDodecamer, respectively. (E)-KN-93 phosphate can be used in research on epilepsy, depression, and arrhythmias..
    (E)-KN-93 phosphate
  • HY-111247
    Ro 09-0680 87112-49-0 98.87%
    Ro 09-0680 is a potent inhibitor of rabbit platelet aggregation induced by Collagen with an IC50 of 6.6 μM.
    Ro 09-0680
  • HY-111326
    Naphazoline 835-31-4 99.74%
    Naphazoline (Naphthazoline) is a potent α-adrenergic receptor agonist. Naphazoline reduces vascular hyperpermeability and promotes vasoconstriction. Naphazoline reduces the levels of inflammatory factors (TNF-α, IL-1β and IL-6), cytokines (IFN-γ and IL-4), IgE, GMCSF, and NGF. Naphazoline can be used for non-bacterial conjunctivitis research.
    Naphazoline
  • HY-112071
    Prenalterol 57526-81-5 99.18%
    Prenalterol is a selective β1-adrenergic receptor agonist. Prenalterol has no effect on gut smooth muscle contractile activity. Prenalterol can be used for researching cardiovascular disease.
    Prenalterol
  • HY-112824
    L-162313 151488-11-8 98.51%
    L-162313 is a non-peptide angiotensin II AT1 and AT2 receptor agonist, with IC50 values of 1.1 and 2.0 nM for AT1 and AT2 receptor, respectively. L-162313 can be used for the research of vasoconstriction, aldosterone release, and cardiovascular growth.
    L-162313
  • HY-113492
    5(S)15(S)-DiHETE 82200-87-1 99.0%
    5(S)15(S)-DiHETE is an “activated” intermediate, inhibits platelet aggregation with an IC50 of 1.3 μM. 5(S)15(S)-DiHETE enhances the rate of either LXA4 or LXB4 biosynthesis.
    5(S)15(S)-DiHETE
  • HY-113495
    Deoxypyridinoline 83462-55-9
    Deoxypyridinoline is an endogenous metabolite present in Urine that can be used for the research of Heart Failure.
    Deoxypyridinoline
  • HY-114285
    L-161638 150484-73-4 98.03%
    L-161638 is a potent, selective and orally active AT2 receptor antagonist. L-161638 can be used for the research of cardiovascular disease, such as hypertension.
    L-161638
  • HY-114683
    KS370G 105955-01-9 99.71%
    KS370G is an orally active hypoglycemic and cardiovascular protective agent. KS370G improves left ventricular hypertrophy and function in pressure-overload mice heart. KS370G reduces renal obstructive nephropathy.
    KS370G
  • HY-117658
    GSK-114 1301761-96-5 99.52%
    GSK-114 is a highly selective, orally active TNNI3K inhibitor (IC50= 25 nM). GSK-114 shows a 40-fold selectivity for TNNI3K over B-Raf kinase (IC50= 1 μM). Cardiac troponin I-interacting kinase (TNNI3K or CARK) is a member of the tyrosine-like kinase family that is selectively expressed in heart tissue.
    GSK-114
  • HY-117820
    TASP0390325 1642187-96-9 ≥99.0%
    TASP0390325 is a high affinity and orally active arginine vasopressin receptor 1B (V1B receptor) antagonist with antidepressant and anxiolytic activities.
    TASP0390325
  • HY-117853
    Atreleuton 154355-76-7 99.9%
    Atreleuton (ABT-761) is a selective, reversible, and orally bioavailable 5-Lipoxygenase (5-LO) inhibitor. Atreleuton (ABT-761) exhibits potent and selective inhibition of leukotriene formation. Atreleuton is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Atreleuton
Cat. No. Product Name / Synonyms Application Reactivity